FMR LLC and Abigail P. Johnson filed Amendment No. 6 to their Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of common stock in Avalo Therapeutics Inc. as of October 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each report beneficial ownership of 474,359 shares of Avalo Therapeutics Inc. common stock (CUSIP 05338F306).
  • Percent of class: The 474,359 shares represent 0.9% of the outstanding class, according to the filing.
  • Sole voting power (FMR LLC): FMR LLC reports sole voting power over 474,127 shares, with zero shared voting power.
  • Sole dispositive power: FMR LLC reports sole dispositive power over 474,359 shares; Abigail P. Johnson separately reports sole dispositive power over the same 474,359 shares.
  • Triggering event date: The date of the event requiring this filing is stated as October 30, 2026.
  • Ordinary course certification: Both reporting persons certify the securities "were acquired and are held in the ordinary course of business" and not for the purpose of changing or influencing control of the issuer.

FMR LLC and Abigail P. Johnson Disclose Sub-1% Stake in Avalo Therapeutics

According to the filing, FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, submitted Amendment No. 6 to its Schedule 13G disclosing its position in the common stock of Avalo Therapeutics Inc., whose principal offices are listed at 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087. The event that required the filing occurred on October 30, 2026, and the statement was signed on November 5, 2026.

The filing reports that FMR LLC, identified as a parent holding company (type "HC"), holds aggregate beneficial ownership of 474,359 shares, with sole voting power over 474,127 shares and sole dispositive power over 474,359 shares. Abigail P. Johnson, a U.S. citizen identified as an individual (type "IN"), is also listed as a reporting person with the same aggregate beneficial ownership of 474,359 shares, though with zero sole voting power and sole dispositive power over 474,359 shares. Neither reporting person reports any shared voting or dispositive power.

The filing states that one or more other persons have the right to receive or direct the receipt of dividends from, or proceeds from the sale of, the common stock of Avalo Therapeutics Inc., but notes that "no one other person's interest in the COMMON STOCK of AVALO THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK." The filing references Exhibit 99 for identification of the subsidiary that acquired the securities on behalf of the parent holding company. The statement was signed by Stephanie J. Brown under a power of attorney on behalf of both FMR LLC and Abigail P. Johnson.

What Was Disclosed

FMR LLC and Abigail P. Johnson filed Amendment No. 6 to Schedule 13G, disclosing aggregate beneficial ownership of 474,359 shares, or 0.9%, of Avalo Therapeutics Inc. common stock, triggered by an event on October 30, 2026.